Pfizer Piotroski F Score

PFE
 Stock
  

USD 49.21  0.36  0.73%   

This module uses fundamental data of Pfizer to approximate its Piotroski F score. Pfizer F Score is determined by combining nine binary scores representing 3 distinct fundamental categories of Pfizer Inc. These three categories are profitability, efficiency, and funding. Some research analysts and sophisticated value traders use Piotroski F Score to find opportunities outside of the conventional market and financial statement analysis.They believe that some of the new information about Pfizer financial position does not get reflected in the current market share price suggesting a possibility of arbitrage. Please check Pfizer Altman Z Score, Pfizer Correlation, Pfizer Valuation, as well as analyze Pfizer Alpha and Beta and Pfizer Hype Analysis.
  
Pfizer Issuance Repayment of Debt Securities is projected to based on the last few years of reporting. The past year's Issuance Repayment of Debt Securities was at 7.89 Billion. The current year Debt to Equity Ratio is expected to grow to 0.50, whereas Debt Non Current is forecasted to decline to about 31.3 B. Pfizer Inventory Turnover is projected to increase slightly based on the last few years of reporting. The past year's Inventory Turnover was at 3.60. The current year Accounts Payable Turnover is expected to grow to 16.57, whereas Long Term Debt to Equity is forecasted to decline to 0.45.
At this time, it appears that Pfizer's Piotroski F Score is Healthy. Although some professional money managers and academia have recently criticized Piotroski F-Score model, we still consider it an effective method of predicting the state of the financial strength of any organization that is not predisposed to accounting gimmicks and manipulations. Using this score on the criteria to originate an efficient long-term portfolio can help investors filter out the purely speculative stocks or equities playing fundamental games by manipulating their earnings..
6.0
Piotroski F Score - Healthy
1
Current Return On AssetsPositiveFocus
2
Change in Return on AssetsIncreasedFocus
3
Cash Flow Return on AssetsPositiveFocus
4
Current Quality of Earnings (accrual)DecreasingFocus
5
Asset Turnover GrowthDecreaseFocus
6
Current Ratio ChangeIncreaseFocus
7
Long Term Debt Over Assets ChangeLower LeverageFocus
8
Change In Outstending SharesIncreaseFocus
9
Change in Gross MarginIncreaseFocus

Pfizer Piotroski F Score Drivers

The critical factor to consider when applying the Piotroski F Score to Pfizer is to make sure Pfizer is not a subject of accounting manipulations and runs a healthy internal audit department. So, if Pfizer's auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back. Below are the main accounts that are used in the Piotroski F Score model. By analyzing the historical trends of the mains drivers, investors can determine if Pfizer's financial numbers are properly reported.
Current ValueLast YearChange From Last Year 10 Year Trend
Weighted Average Shares Diluted6.8 B5.7 B
Fairly Up
Decreasing
Slightly volatile
Weighted Average Shares6.7 B5.6 B
Fairly Up
Decreasing
Slightly volatile
Return on Average Assets14.1313.0948
Significantly Up
Increasing
Slightly volatile
Net Cash Flow from Operations35.2 B32.6 B
Significantly Up
Increasing
Slightly volatile
Current Liabilities35.1 B42.7 B
Significantly Down
Increasing
Slightly volatile
Total Liabilities113.8 B104.3 B
Significantly Up
Decreasing
Very volatile
Gross Margin77.6762.0842
Significantly Up
Decreasing
Slightly volatile
Total Debt55.8 B60 B
Significantly Down
Increasing
Slightly volatile
Asset Turnover0.390.4843
Significantly Down
Increasing
Slightly volatile
Current Assets60.1 B59.7 B
Slightly Up
Decreasing
Slightly volatile
Total Assets196 B181.5 B
Significantly Up
Decreasing
Stable

Pfizer Inc F Score Driver Matrix

One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to project the various growth rates. Understanding the correlation between Pfizer's different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards Pfizer in a much-optimized way.

About Pfizer Piotroski F Score

F-Score is one of many stock grading techniques developed by Joseph Piotroski, a professor of accounting at the Stanford University Graduate School of Business. It was published in 2002 under the paper titled Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers. Piotroski F Score is based on binary analysis strategy in which stocks are given one point for passing 9 very simple fundamental tests, and zero point otherwise. According to Mr. Piotroski's analysis, his F-Score binary model can help to predict the performance of low price-to-book stocks.

Weighted Average Shares

6.68 Billion

Pfizer Weighted Average Shares is projected to decrease significantly based on the last few years of reporting. The past year's Weighted Average Shares was at 5.6 Billion

Pfizer Current Valuation Drivers

We derive many important indicators used in calculating different scores of Pfizer from analyzing Pfizer's financial statements. These drivers represent accounts that assess Pfizer's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Pfizer's important valuation drivers and their relationship over time.
201720182019202020212022 (projected)
Net Income Per Employee236.23 K120.7 K184.29 K122.16 K278.23 K300.19 K
Revenue Per Employee582.55 K580.6 K586.07 K532.4 K1.03 M1.11 M
Average Assets170.91 B170.32 B164.21 B162.39 B146.15 B149.93 B
Earnings Before Interest Taxes and Depreciation Amortization EBITDA17.94 B17.76 B23.64 B12.31 B29.27 B23.13 B
Earnings Before Interest Taxes and Depreciation Amortization USD14.1 B18.53 B18.24 B23.67 B21.3 B19.62 B
Earnings before Tax8.34 B12.26 B11.86 B17.66 B20.31 B18.49 B
Average Equity62.17 B62.22 B68.67 B61.66 B55.49 B59.93 B
Enterprise Value239.08 B257.07 B289.8 B266.7 B306.71 B295.03 B
Free Cash Flow14.19 B14.59 B13.63 B9.99 B8.99 B10.72 B
Invested Capital72.89 B78.83 B79.54 B87.01 B78.31 B80.24 B
Invested Capital Average79.13 B77.76 B73.71 B84.26 B75.84 B79.17 B
Market Capitalization197.1 B215.9 B252.32 B216.83 B249.35 B242.51 B
Tangible Asset Value64.52 B67.1 B70.8 B73.47 B66.12 B70.04 B
Working Capital7.83 B10.71 B18.07 B(4.5 B)(4.05 B)(4.16 B)

Pfizer ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Pfizer's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Pfizer's managers, analysts, and investors.
Environment Score
Governance Score
Social Score

About Pfizer Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Pfizer Inc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pfizer using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pfizer Inc based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York. Pfizer operates under Drug ManufacturersGeneral classification in the United States and is traded on New York Stock Exchange. It employs 79000 people.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Pfizer without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Options Analysis Now

   

Options Analysis

Analyze and evaluate options and option chains as a potential hedge for your portfolios
All  Next Launch Module

Currently Active Assets on Macroaxis

Please check Pfizer Altman Z Score, Pfizer Correlation, Pfizer Valuation, as well as analyze Pfizer Alpha and Beta and Pfizer Hype Analysis. Note that the Pfizer Inc information on this page should be used as a complementary analysis to other Pfizer's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Content Syndication module to quickly integrate customizable finance content to your own investment portal.

Complementary Tools for Pfizer Stock analysis

When running Pfizer Inc price analysis, check to measure Pfizer's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pfizer is operating at the current time. Most of Pfizer's value examination focuses on studying past and present price action to predict the probability of Pfizer's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Pfizer's price. Additionally, you may evaluate how the addition of Pfizer to your portfolios can decrease your overall portfolio volatility.
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Go
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Go
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Go
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Go
Is Pfizer's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pfizer. If investors know Pfizer will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pfizer listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth YOY
0.055
Market Capitalization
276.2 B
Quarterly Revenue Growth YOY
(0.06) 
Return On Assets
0.13
Return On Equity
0.36
The market value of Pfizer Inc is measured differently than its book value, which is the value of Pfizer that is recorded on the company's balance sheet. Investors also form their own opinion of Pfizer's value that differs from its market value or its book value, called intrinsic value, which is Pfizer's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pfizer's market value can be influenced by many factors that don't directly affect Pfizer's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pfizer's value and its price as these two are different measures arrived at by different means. Investors typically determine Pfizer value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pfizer's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.